---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-007282"
form_type: "8-K"
ticker: null
cik: "0001718108"
company_name: "Surface Oncology, Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T16:05:01.463472+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surface Oncology receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq deficiency letter on Jan 6, 2023, for failing minimum $1.00 bid price for 30 consecutive days.
- Has 180 calendar days, until July 5, 2023, to regain compliance with Rule 5550(a)(2).
- Can regain compliance if bid price closes at $1.00 or more for 10 consecutive business days before deadline.
- If not compliant by July 5, may seek a second 180-day period or face potential delisting.
- Company is monitoring price and considering options, including a possible reverse stock split.

## SEC filing metadata
- accession: 0001193125-23-007282
- form_type: 8-K
- cik: 0001718108
- company_name: Surface Oncology, Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1718108/000119312523007282/0001193125-23-007282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1718108/000119312523007282/d396065d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-007282
- JSON: https://secwatch.observer/filing/0001193125-23-007282.json
- Plain text: https://secwatch.observer/filing/0001193125-23-007282.txt

## Key facts
- Listing & Compliance Notices
  Surface Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 6, 2023, Surface Oncology, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1718108/000119312523007282/0001193125-23-007282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.